Search

Your search keyword '"Bechtold, Dorte"' showing total 8 results
Start Over Author "Bechtold, Dorte"
8 results on '"Bechtold, Dorte"'

3. Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).

Author

Schuh, Anna, Ayvaz, Goksun, Baldeschi, Lelio, Baretić, Maja, Bechtold, Dorte, Boschi, Antonella, Brix, Thomas Heiberg, Burlacu, Maria-Cristina, Ciric, Jasmina, Covelli, Danila, Currò, Nicola, Donati, Simone, Eckstein, Anja K., Fichter, Nicole, Führer, Dagmar, Horn, Maren, Jabłońska-Pawlak, Anna, Mandić, Jelena Juri, Kahaly, George J., and Konuk, Onur

Abstract

Background Graves' orbitopathy (GO) is subject to epidemiological and care-related changes. Aim of the survey was to identify trends in presentation of GO to the European Group On Graves' Orbitopathy (EUGOGO) tertiary referral centres and initial management over time. Methods Prospective observational multicentre study. All new referrals with diagnosis of GO within September-December 2019 were included. Clinical and demographic characteristics, referral timelines and initial therapeutic decisions were recorded. Data were compared with a similar EUGOGO survey performed in 2012. Results Besides age (mean age: 50.5±13 years vs 47.7±14 years; p 0.007), demographic characteristics of 432 patients studied in 2019 were similar to those in 2012. In 2019, there was a decrease of severe cases (9.8% vs 14.9; p<0.001), but no significant change in proportion of active cases (41.3% vs 36.6%; p 0.217). After first diagnosis of GO, median referral time to an EUGOGO tertiary centre was shorter (2 (0-350) vs 6 (0-552) months; p<0.001) in 2019. At the time of first visit, more patients were already on antithyroid medications (80.2% vs 45.0%; p<0.001) or selenium (22.3% vs 3.0%; p<0.001). In 2019, the initial management plans for GO were similar to 2012, except for lid surgery (2.4% vs 13.9%; p<0.001) and prescription of selenium (28.5% vs 21.0%; p 0.027). Conclusion GO patients are referred to tertiary EUGOGO centres in a less severe stage of the disease than before. We speculate that this might be linked to a broader awareness of the disease and faster and adequate delivered treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)

Author

Schuh, Anna, primary, Ayvaz, Goksun, additional, Baldeschi, Lelio, additional, Baretić, Maja, additional, Bechtold, Dorte, additional, Boschi, Antonella, additional, Brix, Thomas Heiberg, additional, Burlacu, Maria-Cristina, additional, Ciric, Jasmina, additional, Covelli, Danila, additional, Currò, Nicola, additional, Donati, Simone, additional, Eckstein, Anja K, additional, Fichter, Nicole, additional, Führer, Dagmar, additional, Horn, Maren, additional, Jabłońska-Pawlak, Anna, additional, Juri Mandić, Jelena, additional, Kahaly, George J, additional, Konuk, Onur, additional, Langbein, Amelie, additional, Lanzolla, Giulia, additional, Marcocci, Claudio, additional, Marinò, Michele, additional, Miśkiewicz, Piotr, additional, Beleslin, Biljana Nedeljkovic, additional, Pérez-Lázaro, Antonia, additional, Pérez-López, Marta, additional, Ponto, Katharina A, additional, Quinn, Anthony, additional, Rudofsky, Gottfried, additional, Salvi, Mario, additional, Schittkowski, Michael P, additional, Tanda, Maria Laura, additional, Toruner, Fusun, additional, Vaidya, Bijay, additional, and Hintschich, Christoph R, additional

Published
2023
Full Text
View/download PDF

5. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

Author

Bartalena, L, primary, Kahaly, G J, additional, Baldeschi, L, additional, Dayan, C M, additional, Eckstein, A, additional, Marcocci, C, additional, Marinò, M, additional, Vaidya, B, additional, Wiersinga, W M, additional, _, _, additional, Ayvaz, Goksun, additional, Konuk, Onur, additional, Ciric, Jasmina, additional, Beleslin, Bijliana, additional, Boschi, Antonella, additional, Cristina Burlacu, Maria, additional, Morris, Dan, additional, Le Moli, Rosario, additional, Marino, Antonio, additional, McKee, Justin, additional, Zammit, Nicola, additional, Führer, Dagmar, additional, Pereni, Ioana, additional, Schittkowski, Michael, additional, Raddatz, Dirk, additional, Lee, Vickie, additional, Meeran, Karim, additional, Abeillon, Juliette, additional, Soui Thcong, Thia, additional, Ponto, Katharina, additional, Muller, Ilaria, additional, Currò, Nicola, additional, Hintschich, Christoph, additional, Gärtner, Roland, additional, Pearce, Simon, additional, Clarke, Lucy, additional, Brix, Thomas, additional, Bechtold, Dorte, additional, Rudovfsky, Gottfried, additional, Fichter, Nicole, additional, Du Pasquier, Laurence, additional, Meney, Julia, additional, Menconi, Francesca, additional, Lanzolla, Giulia, additional, Sundar, Gangadhara, additional, Peiling Yung, Samantha, additional, Boboridis, Kostas, additional, Anagnostis, Panagiotis, additional, Pérez Lopez, Marta, additional, Javier Sanchez, Carlos, additional, Laura Tanda, Maria, additional, Donati, Simone, additional, Papp, Andrea, additional, Li, Shuren, additional, Jablonska, Anna, additional, Miskiewicz, Piotr, additional, Juri Mandic, Jelena, additional, and Baretic, Maja, additional

Published
2021
Full Text
View/download PDF

6. Plexiform neurofibroma of the eye region occurring in patients without neurofibromatosis type 1

Author

Bechtold, Dorte, Hove, Hanne D, Prause, Jan Ulrik, Heegaard, Steffen, Toft, Peter B, Bechtold, Dorte, Hove, Hanne D, Prause, Jan Ulrik, Heegaard, Steffen, and Toft, Peter B

Abstract

The purpose of the present study was to investigate the correlation between Plexiform Neurofibroma (PN) of the eye region and Neurofibromatosis type 1 (NF1). According to the textbooks of ophthalmology, PN and NF1 are very closely linked. Our clinical experience raised doubts about this, however.

Published
2012

8. [Orbital decompression in non-thyroid-associated diseases].

Author

Ketharanathan B, Andersen MS, Pedersen CB, Darling P, Jakobseb J, Bechtold D, Molander LD, Gampenrieder N, Dahlrot RH, Nguyen N, Poulsen FR, and Halle B

Subjects
Decompression, Humans, Hypoxia, Oxygen, Hyperbaric Oxygenation, Hyperoxia
Abstract

Hypoxia triggers hypoxia-inducible factor (HIF). Not only hypoxia triggers downstream HIF target genes for transcription, as intermittent hyperoxia also possesses similar capabilities, suggesting that fluctuations in oxygen availability may be equally important for inducing HIF transcription. This review describes some of the mechanisms, whereby intermittent hyperbaric hyperoxia may explain some of the observations during hyperbaric oxygen therapy such as enhanced wound healing, angiogenesis and tissue healing, and concludes that oxidative stress enhances certain antibiotics in infection control.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results